Singapore markets closed

Straits Times Index
3,297.55
-26.98(-0.81%)
Nikkei
38,814.56
+94.09(+0.24%)
Hang Seng
17,941.78
-170.85(-0.94%)
FTSE 100
8,146.86
-16.81(-0.21%)
Bitcoin USD
66,090.59
-100.23(-0.15%)
CMC Crypto 200
1,372.64
-45.24(-3.19%)

Arcutis Biotherapeutics, Inc. (ARQT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

8.63

-0.71

(-7.60%)

At close: 04:00PM EDT

8.78

+0.15

(+1.74%)

After hours:

07:47PM EDT

Loading interactive chart…

Zacks
Wall Street Analysts Think Arcutis Biotherapeutics (ARQT) Could Surge 99.89%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in Arcutis Biotherapeutics (ARQT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Initial data from an early-stage study shows that treatment with Avidity's (RNA) experimental therapy could address the underlying cause of a rare muscle-weakening condition.
Zacks
FDA Expands AstraZeneca's (AZN) Farxiga Label in Pediatric T2D
Following the label expansion, AstraZeneca's (AZN) Farxiga is now approved to improve glycemic control in patients aged 10 years and older with T2D. It was previously approved for such use in adults.